We are a biotechnology company developing innovative medicines intended to improve people’s lives.
We discover and develop new medicines in order to offer new and better treatment options to patients affected by inflammatory diseases, cystic fibrosis, metabolic diseases, fibrosis, and other diseases.
Our unique Target Discovery Platform is transforming how medicines are discovered. Today our pipeline encompasses potential treatments in inflammatory diseases, fibrosis, metabolic diseases and infectious diseases.
Our no fear of failure culture fuels our ambition to explore uncharted territory in drug discovery.
We are relentless in our drive to search for medicines with new modes of action, which address the disease itself rather than just treating the symptoms.
... Galapagos UK
We are dedicated to bringing new medicines to UK patients, starting with our first medicine which is a potential treatment for various inflammatory diseases.
"I’m delighted to be leading the Galapagos team in the UK as we build our UK organisation from scratch. We will go above and beyond to provide patients with innovative treatments stemming from Galapagos' rich pipeline, aiming to address unmet medical needs for patients in the UK. Or as we like to put it at Galapagos: Pioneering for patients. We discover, we dare, we care."
Emma Chaffin, Country Head at Galapagos UK
For over 20 years, we have been on a relentless search for medicines with new modes of action, addressing the disease itself rather than just treating the symptoms. With our research and development aiming to discover novel drugs, we aspire to create innovative medicines that will improve patients’ lives.
We are pioneering for patients, transforming drug discovery with our unique target discovery platform. Most chronic diseases and disorders are caused by a disruption in the way in which certain proteins function. Using our discovery platform, based on research with human cells, we discover those proteins – which we call ‘targets’ – that play a key role in causing these diseases. Next, we develop small molecules which slow down or suppress the target proteins, restoring the balance and therefore positively influencing the course of diseases.
Galapagos has a database of over 6000 genes to identify potential targets that we can use to impact disease progression. Doing so, we aim to address its root cause rather than just treating the symptoms.
"We continue to leverage our unique target discovery engine, as we keep pushing forward to discover novel targets and develop new mode of action molecules, aiming to improve patients' lives around the world."
Onno van de Stolpe, CEO Galapagos
Before a medicine is made available for patients and prescribers, the benefits and risks must be understood and evaluated by regulatory agencies. Galapagos conducts clinical trials to understand the safety, tolerability and pharmacokinetics of new compounds before assessing their efficacy in treating disease. Information about ongoing clinical trials for Galapagos’ investigational drugs is available at www.clinicaltrials.gov*.
Alternatively, you can contact our Medical Information department.
We are always looking for talented individuals to join us on our journey; who are passionate about life sciences and want to use their knowledge to improve lives.
Make it happen
Act as a pioneer
Raise the bar
Are you ready to join us in the pursue of medical breakthroughs?
Hurry over to our careers page to discover more about opportunities at Galapagos in the UK.